Paper Details

  1. Home
  2. Paper Details

Bempedoic Acid's Use as an Adjunct in Lowering Low-Density Lipoprotein Cholesterol in Patients With Coronary Artery Disease: A Systematic Review.

Author: BadlaOmar, CaleroMaria Jose, DawoodSarah N, GoitRaman, JoshaghaniNarges, KhanSafeera, NiajAhmad, RabihAhmad M, RamanAishwarya, SaddikSamia E, UpretyManish, VillaNicole, VillanuevaMaria Resah B

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Bempedoic acid (BDA) is a new lipid-lowering drug that inhibits adenosine triphosphate (ATP) citrate lyase. This review evaluated the efficacy and safety of BDA in lowering LDL-C levels in patients with coronary artery disease (CAD). BDA in combination with ezetimibe showed good evidence of LDL-C lowering effects. In patients on maximally tolerated statins, BDA significantly reduced LDL-C levels, high sensitivity C-reactive protein (HsCRP), and triglyceride levels. BDA appears to be a promising alternative to current lipid-lowering agents.
Paper Details　
Original Abstract of the Article :
Coronary artery disease (CAD) is one of the leading causes of death worldwide. Atherosclerosis begins in childhood as fatty streaks, progresses with age, and lifestyle influences the progression of atherosclerotic plaque. Over time, with significant narrowing of the blood vessels, blood flow into th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632934/

データ提供：米国国立医学図書館（NLM）

Bempedoic Acid's Use as an Adjunct in Lowering Low-Density Lipoprotein Cholesterol in Patients With Coronary Artery Disease: A Systematic Review

As a research-driven camel, I find the ongoing search for new and effective treatments fascinating! This study focuses on bempedoic acid (BDA), a novel lipid-lowering drug that may be useful in treating coronary artery disease (CAD).

The authors conducted a systematic review of studies investigating the efficacy and safety of BDA in lowering LDL-C levels in patients with CAD. They found that BDA, either alone or in combination with other lipid-lowering drugs, demonstrated a significant reduction in LDL-C levels. BDA was generally well-tolerated, although some patients experienced elevated uric acid levels. The CLEAR Outcomes clinical trial, scheduled to be completed by December 2022, will provide further insights into the long-term effects of BDA.

A Promising New Drug for Coronary Artery Disease

This systematic review suggests that BDA may be a promising new drug for treating coronary artery disease. The study found that BDA effectively lowered LDL-C levels, a significant risk factor for heart disease. This is promising news for patients with CAD who need additional help in managing their cholesterol levels.

Understanding the Potential Benefits and Risks of Bempedoic Acid

While the review highlights the potential benefits of BDA, it is important to understand the potential risks. The most common side effect reported was elevated uric acid levels. This underscores the importance of monitoring uric acid levels in patients taking BDA. The results of the ongoing CLEAR Outcomes trial will provide further information about the long-term safety and efficacy of BDA.

Dr.Camel's Conclusion

Just as a camel needs to be cautious about dehydration in the desert, doctors need to be aware of the potential side effects of new medications. This study offers a promising new approach to lowering LDL-C levels in patients with coronary artery disease, but it's important to carefully consider the potential risks and benefits before making any treatment decisions.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-11-10
Further Info :

Pubmed ID

36348882

DOI: Digital Object Identifier

PMC9632934

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.